A retrospective study on the prevalence of anti-phospholipid antibodies, thrombotic events and cutaneous signs of vasculopathy in 173 hospitalized COVID-19 patients.

Giulia GaspariniPaola CanepaSimonetta VerdianiLuca CarmiscianoEmanuele CozzaniDenise De GraziaOrsi AndreaGiancarlo IcardiAurora Parodi

Published in: International journal of immunopathology and pharmacology (2021)

Anti-phospholipid antibodies cannot be considered responsible for hypercoagulability and thrombotic events in COVID-19 patients. In COVID-19 patients, livedo reticularis and acrocyanosis do not appear to be cutaneous manifestations of APS.

Keyphrases

sars cov
fatty acid
risk factors